Linear Regression Analysis and Validation Studies of Insulin-Like Growth Factor (IGF-1) Receptor Inhibitors

R. Rambabu*, P. Srinivasa Rao**
* Associate Professor and Head, Department of Computer Science & Engineering, Rajamahendri Institute of Engineering & Technology, Rajahmundry, India.
** Professor, Department of Computer Science & Systems Engineering, College of Engineering, Andhra University, Visakhapatnam, India.
Periodicity:June - August'2016
DOI : https://doi.org/10.26634/jit.5.3.8139

Abstract

To delineate the dependency of physico-chemical properties on activity of inhibitors, a python program was written to study the linear regression analysis on a set of Insulin Growth Factor – 1R inhibitors. About 87 IGF-1 receptor inhibitors were selected from published literature with few independent variables such as Molecular weight, Hydrogen bond donors, acceptors, logP and a number of freely rotatable bonds, 5- and 6- membered aromatic rings, Randic, Balaban indices, LUMO, HOMO, Dipole, Lipole and molar refractivity were selected. The relationship between dependent variable (log1/IC ) and independent variables was established by linear regression analysis using python code. A linear regression 50 2 analysis resulted in F-test: 8.812, r value: 0.794 and r value of 0.631, respectively. Inter-correlation between variables of the proposed regression model was checked to know about their independence. It is observed that compounds 13, 53 and 63 has standardized residuals -2.011, 2.309 and 2.227 respectively and can safely be excluded from the data set. Leverages and standardized residuals resulted in similar outcomes, but leverage analysis was able to find three more outlying data, finally 6 compounds were omitted from the dataset of 87 compounds, and the remaining 81 were divided as 76 molecule training set and a 5 molecule validation set. The predicted values of test set data (actual vs predicted) 2 2 when Equation (2) was applied and the regression coefficient (r ) obtained was 0.9686 and regression coefficient (r ) o passing through origin was plotted, which is 0.9326 within the limits. Regression plot between actual vs. predicted values 2 2 of compounds and vice versa of test data set showed r = 0.9686 and r = 0.9465, which suggests the predictive ability of o 2 the regression equation. From the analysis of test set, the regression equation is said to have predictive ability with R = cv,ext 2 2 2 2 2 2 2 0.99, R = 0.97, (R – R ) / R = 0.03 and (R – R ) / R = 0.02 and k = 1.01 and k' = 0.99 respectively.

Keywords

Insulin Like Growth Factor -1 Receptor, Linear Regression, Regression Coefficient, Regression Plot, Outliers.

How to Cite this Article?

Rambabu. R and Rao. P. S (2016). Linear Regression Analysis and Validation Studies of Insulin-Like Growth Factor (IGF-1) Receptor Inhibitors. i-manager’s Journal on Information Technology, 5(3), 30-43. https://doi.org/10.26634/jit.5.3.8139

References

[1]. Baserga, R. (2005). “The Insulin-like Growth Factor-I Receptor as a Target for Cancer Therapy”. Expert Opinion on Therapeutic Targets, Vol. 9, No. 4, pp. 753-768.
[2]. Pollak, M. N., Schernhammer, E. S., and Hankinson, S. E. (2004). “Insulin-like Growth Factors and Neoplasia”. Nature Reviews Cancer, Vol. 4, No. 7, pp. 505-518.
[3]. Baserga, R., Peruzzi, F., and Reiss, K. (2003). “The IGF-1 Receptor in Cancer Biology”. International Journal of Cancer, Vol. 107, No. 6, pp. 873-877.
[4]. Yu, H., and Rohan, T. (2000). “Role of the Insulin-like Growth Factor Family in Cancer Development and Progression”. Journal of the National Cancer Institute, Vol. 92, No. 18, pp. 1472-1489.
[5]. Baserga, R. (1995). “The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?”. Cancer Research, Vol. 55, No. 2, pp. 249-252.
[6]. Breuhahn, K., Nussbaum, T., Singer, S., and Schirmacher, P. (2006). “The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment”. Current Cancer Therapy Reviews, Vol. 2, No. 2, pp. 157-167.
[7]. He, G., Sung, Y. M., Di Giovanni, J., and Fischer, S. M. (2006). “Thiazolidinediones Inhibit Insulin-Like Growth Factor-I–Induced Activation of p70S6 Kinase and Suppress Insulin-Like Growth Factor-I Tumor-Promoting Activity”. Cancer Research, Vol. 66, No. 3, pp.1873-1878.
[8]. Garcia-Echeverria, C. (2006). “Medicinal Chemistry Approaches to Target the Kinase activity of IGF-1R”. IDrugs: the Investigational Drugs Journal, Vol. 9, No. 6, pp. 415-419.
[9]. Haluska, P., Carboni, J. M., Loegering, D. A., Lee, F. Y., Wittman, M., Saulnier, M. G., and Kaufmann, S. H. (2006). “In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417”. Cancer Research, Vol. 66, No. 1, pp. 362-371.
[10]. Wittman, M., Carboni, J., Attar, R., Bala subramanian, B., Balimane, P., Brassil, P., and Eummer, J. (2005). “Discovery of a 1 H-Benzoimidazol-2-yl)-1 Hpyridin- 2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity”. Journal of Medicinal Chemistry, Vol. 48, No. 18, pp. 5639- 5643.
[11]. Carboni, J.M., Lee, A.V., Hadsell, D.L., Rowley, B.R., Lee, F.Y., Bol, D.K., and Hurlburt, W. (2005). “Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor”. Cancer Research, Vol. 65, No. 9, pp. 3781-3787.
[12]. Velaparthi, U., Liu, P., Balasubramanian, B., Carboni, J., Attar, R., Gottardis, M., and Vyas, D. (2007). “Imidazole moiety replacements in the 3-(1H-benzo [d] imidazol-2-yl) pyridin-2 (1H)-one inhibitors of insulin-like growth factor receptor-1 (IGF-1R) to improve cytochrome P450 profile”. Bioorganic & Medicinal Chemistry Letters, Vol. 17, No. 11, pp. 3072-3076.
[13]. Saulnier, M. G., Frennesson, D. B., Wittman, M. D., Zimmermann, K., Velaparthi, U., Langley, D. R., and Greer, A. (2008). “2-(1H-Imidazol-4-yl) ethanamine and 2- (1H-pyrazol-1-yl) ethanamine side chain variants of the IGF-1R inhibitor BMS-536924”. Bioorganic & Medicinal Chemistry Letters, Vol. 18, No. 5, pp. 1702-1707.
[14]. Zimmermann, K., Wittman, M. D., Saulnier, M. G., Velaparthi, U., Sang, X., Frennesson, D. B., and Li, A. (2010). “SAR of PXR transactivation in benzimidazolebased IGF-1R kinase inhibitors”. Bioorganic & Medicinal Chemistry Letters, Vol. 20, No. 5, pp.1744-1748.
[15]. Velaparthi, U., Saulnier, M. G., Wittman, M. D., Liu, P., Frennesson, D. B., Zimmermann, K., and Clarke, W. (2010). “Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substitutedpiperazin- 1-yl)-4-methyl-1H-benzimidazol-2-yl]-1Hpyridine- 2-one”. Bioorganic & Medicinal Chemistry Letters, Vol. 20, No. 10, pp. 3182-3185.
[16]. Wittman, M. D., Balasubramanian, B., Stoffan, K., Velaparthi, U., Liu, P., Krishnanathan, S., and Gottardis, M. (2007). “Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase”. Bioorganic & Medicinal Chemistry Letters, Vol.17, No. 4, pp. 974-977.
[17]. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P.J. (2012). “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings”. Advanced Drug Delivery Reviews, Vol. 64, pp. 4-17.
[18]. Afantitis, A., Melagraki, G., Sarimveis, H., Koutentis, P. A., Markopoulos, J., and Igglessi-Markopoulou, O. (2006). “A novel QSAR model for predicting induction of apoptosis by 4-aryl-4H-chromenes”. Bioorganic & Medicinal Chemistry, Vol. 14, No. 19, pp. 6686-6694.
[19]. Kim, D., Hong, S.I., and Lee, D.S. (2006). “The quantitative structure-mutagenicity relationship of polycylic aromatic hydrocarbon metabolites ”. International Journal of Molecular Sciences, Vol. 7, No. 12, pp. 556-570.
[20]. Jaworska, J., Nikolova-Jeliazkova, N., and Aldenberg, T. (2005). “QSAR applicability domain estimation by projection of the training set descriptor space: A review”. ATLA-NOTTINGHAM, Vol. 33, No. 5, pp. 445.
[21]. Afantitis, A., Melagraki, G., Sarimveis, H., Koutentis, P. A., Markopoulos, J., and Igglessi-Markopoulou, O. (2006). “Investigation of substituent effect of 1-(3, 3- diphenylpropyl)-piperidinylphenylacetamides on CCR5 binding affinity using QSAR and virtual screening techniques”. Journal of Computer-Aided Molecular Design, Vol. 20, No. 2, pp. 83-95.
[22]. Golbraikh, A., and Tropsha, A. (2002). “Beware of q 2!”. Journal of Molecular Graphics and Modelling, Vol. 20, No. 4, pp. 269-276.
[23].Hall, L.H., Mohney, B., and Kier, L.B. (1991). “The electrotopological state: structure information at the atomic level for molecular graphs”. Journal of Chemical Information and Computer Sciences, Vol. 31, No. 1, pp. 76-82.
If you have access to this article please login to view the article or kindly login to purchase the article

Purchase Instant Access

Single Article

North Americas,UK,
Middle East,Europe
India Rest of world
USD EUR INR USD-ROW
Pdf 35 35 200 20
Online 35 35 200 15
Pdf & Online 35 35 400 25

Options for accessing this content:
  • If you would like institutional access to this content, please recommend the title to your librarian.
    Library Recommendation Form
  • If you already have i-manager's user account: Login above and proceed to purchase the article.
  • New Users: Please register, then proceed to purchase the article.